

# Index

## A

- A549 cells, 125, 131, 132, 143, 145, 152
- Actin-myosin alignment, 99–100
- Acute lung injury (ALI)
  - apoptosis, 169
  - BMSCs, 11–12, 35
  - hyperoxia, 128
  - lung function, 40
  - newborns and adults, 34
  - sepsis and mitochondrial dysfunction, 11
  - stem cells, 64
- Acute respiratory distress syndrome (ARDS), 130, 169
- ADMA. *See* Asymmetric dimethyl arginine (ADMA)
- Age-specific expression
  - antioxidant enzyme systems, 184
  - ETS exposure, 196
  - GPx mRNA expression, 186
  - mitochondrial, 180, 182
  - pulmonary cellular injury, 180
  - SOD, 186
  - xenobiotic-metabolizing enzyme systems, 189
- Airway remodeling
  - and ASM cell proliferation, 108
  - COX, 62
  - EMTU, 61–62
  - PBR, 62–63
  - smooth muscle proliferation, 62
- Airway smooth muscle (ASM)
  - components, 93–94
  - ECC (*see* Excitation-contraction coupling (ECC))
  - energy consumption, 103
  - excitation-energy coupling, 104
  - mitochondria, 94
- ALI. *See* Acute lung injury (ALI)
- Allergic bronchial asthma, 12–13, 55
- Antineoplastic drug bleomycin, 143
- Antioxidant
  - age-specific expression, enzyme systems, 184
  - ceruloplasmin, 188
  - and detoxification systems, 184
  - enzymatic and nonenzymatic, 119–120
  - lipid peroxidation, 133
  - mRNA, 188–189
- Antioxidant enzymes (AOEs)
  - asthmatic epithelium, 12
  - environmental toxicants, 184
  - and GSH, 6
  - mitochondrial dysfunction, 17
  - oxidative stress, 16
  - and proteins, 39
  - radiation-induced mitochondrial lipid peroxidation, 128
  - ROS, 31
  - and thiol levels, 17
- AOEs. *See* Antioxidant enzymes (AOEs)
- Apoptosis
  - ALI, 169
  - asthma, 12, 13, 169
  - ATP-dependent process, 179
  - and autophagy, 31–33
  - cell death, 33
  - chemotherapy, 167
  - cigarette smoke, 170
  - COPD, 170
  - cytochrome *c*, 122

Apoptosis (*cont.*)

- FasL, 167
- fibrotic mechanism, 167, 168
- glucocorticoids, 61
- in human lung cancer, 130
- immune response, 31
- and inflammation, 13, 127
- intrinsic mechanism, 168, 169
- IPF, 169
- lung epithelial cell model, 125
- mitochondrial dysfunction, 60–61
- in mouse embryonic cells, 10
- MPT inhibition, 167
- pulmonary artery endothelial cells, 127
- redox-mediated mechanism, 123
- respiration-deficient cell lines, 15
- signaling pathways, 167
- TNF, 167

ARDS. *See* Acute respiratory distress syndrome (ARDS)

## Asthma

- airway remodeling, 61–63
- apoptosis, 60–61
- bronchial epithelium, 53
- calcium homeostasis, 63
- description, 52
- mitochondrial dysfunction, 56–57
- mitochondrial function, 55–56
- mitochondrial genetics (*see* Mitochondrial genetics)
- RNS, 59–60
- ROS, 57–58
- therapeutics, 64–65
- and viral infections, 63–64

## Asymmetric dimethyl arginine (ADMA), 56, 59

## Autonomic and cardiovascular functions, OSA

- blood pressure regulation, 74–75
- heart rate and blood pressure, 73
- hypertension, 73

## Autophagy

- intracellular recycling system, 32
- macroautophagy, 32
- regulation, 32, 33
- sequestosome, 32

**B**

## Baroreflex, 74, 77, 81

## Benzof[a]pyrene (B[a]P) carcinogen, 126

## Blood pressure regulation

- chemoreflex-baroreflex function, 74
- MSNA, 74
- vasoconstrictors, 74–75

## Bone marrow-derived stromal cells (BMSCs), 11–12, 35

BPD. *See* Bronchopulmonary dysplasia (BPD)

## Bronchial asthma, 12, 60, 169

## Bronchopulmonary dysplasia (BPD)

- AOEs, 16
- hyperoxia, 15
- lung alveolarization, 152
- oxidative stress, 16
- pulmonary capillary endothelial cells, 15
- supplemental oxygen therapy, 14

**C**

## Calcium homeostasis and asthma, 63

## Cancer cells, 131, 165–167

## Cardiolipin (CL)

- chemical structure, 121
- cholesterol levels, 123–124
- cytochrome *c*, 122, 123
- deficiency, 123
- dihydroperoxides, 123
- inner mitochondrial membrane, 120
- peroxidation, 123, 127, 128
- remodeling, 121
- ROS-mediated peroxidation, 122, 123

Ca<sup>2+</sup> signaling

- actin-myosin
  - alignment, 99
  - remodeling, 100–101
- ASM model, 95
- and ATP production, 102–106
- cytosolic and mitochondrial, 106
- excitation-contraction coupling time frame, 96–97
- internal loading hypothesis, 102–103
- latch-bridge hypothesis, 102
- mechanical function and ATP hydrolysis, 96–97
- plasma membrane, 95
- RyR channels, 95
- sarcoplasmic reticulum, 95
- sensing and decoding, 106–108
- skeletal muscle actin, 101

## Catalase, 5, 14, 122, 187

## Cell cycle arrest, 148

## Cell death, 10, 31, 128, 149, 167

## Cell signaling

- mitochondrial electron transport system, 16–17
- ROS, 30, 171

## Cellular injury

- bioactivated compounds, 196–197

- oxidant gases, 198–200
  - toxicant exposure, 194–195
  - Chemoreflex, 74, 77, 78
  - Chronic intermittent hypoxia, 72, 77, 81
  - Chronic obstructive pulmonary disease (COPD)
    - apoptosis, 170
    - cytoprotective gene, 40
    - lung diseases, 42
    - prohibitin expression, 35
    - skeletal muscle dysfunction, 170–171
  - CL. *See* Cardiolipin (CL)
  - Clara cells, 180, 188, 195, 197, 199, 200
  - Continuous positive airway pressure (CPAP), 75, 80
  - COPD. *See* Chronic obstructive pulmonary disease (COPD)
  - Cytochrome *c* oxidase (COX), 55, 56, 59, 62, 164
  - Cytochrome P450 (CYP) monooxygenases, 189–191, 195, 197
- D**
- DDR. *See* DNA damage response (DDR)
  - Detoxification systems, 184
  - DNA damage
    - cell cycle arrest, 148
    - cell death, 149
    - cell differentiation, 149–150
    - cellular response, 144–145
    - DDR, 145–147
    - DNA repair, 148–149
    - lesions, 150–151
    - lung disease, 152–153
    - mitochondrial dysfunction, 151–152
    - mtDNA and nuclear DNA, 143–144
    - p53 and mitochondria, 152
  - DNA damage response (DDR)
    - cell cycle arrest, 148
    - effector function, 147
    - sensors, 145–146
    - transducers, 146–147
  - DNA lesions, 150–151
  - DNA repair, 53, 148–149
- E**
- ECC. *See* Excitation-contraction coupling (ECC)
  - EH. *See* Epoxide hydrolase (EH)
  - Eicosanoids, 129–132
  - Electron transport chain (ETC)
    - aconitase activity, mitochondrial, 82
    - asbestos fiber-mediated pulmonary fibrosis, 14
    - cellular oxygen sensor, 34
    - cytochrome *c*, 29, 59
    - electrons shuttling, 142
    - intermembrane space, 29
    - lung cancer, 126
    - mitochondrial toxicity, 178
    - mtDNA, 34, 52, 53
    - NADH, 104
    - oxidative phosphorylation, 119, 152
    - $PO_2$  cells, 164
    - RNS and ROS, 3
    - ROS production, 14
  - EMTU. *See* Epithelial mesenchymal trophic unit (EMTU)
  - Energetics
    - and mechanics, 94
    - neoplastic lung tissue, 126
  - Environmental tobacco smoke (ETS), 195–196
  - Epithelial mesenchymal trophic unit (EMTU), 61–62
  - Epoxide hydrolase (EH), 193
  - ETC. *See* Electron transport chain (ETC)
  - Excitation-contraction coupling (ECC)
    - airway smooth muscle cells, 96–97
    - and excitation-energy coupling, 98
    - mechanical function and ATP hydrolysis, 97–99
    - SERCA, 96
    - 1,4,5-trisphosphate receptors, 95–96
- G**
- Glucuronyl transferase, 193–194
  - Glutamate cysteine ligase catalytic subunit (GCLC), 31, 36, 38
  - Glutamate cysteine ligase modifier subunit (GCLM), 31, 36, 38
  - Glutaredoxins (GRXs), 39
  - Glutathione (GSH)
    - acrolein-induced damage, 130
    - cellular antioxidant, 31
    - cellular redox homeostasis, 119
    - description, 187
    - GCLC and GCLM, 38
    - glutathionylation, 39
    - GRXs, 39
    - lung injury, 40
    - mitochondrial pools, 7
    - non-receptor mechanism, 131
    - rodent studies, 188
    - selenocysteine, 5

- Glutathione (GSH) (*cont.*)  
 thiol-redox status, 119  
 TXNRD2, 39
- Glutathione peroxidase (GPx)  
 description, 186  
 ischemia-reperfusion injury, 6  
 mRNA expression, 186  
 peroxynitrite reductase, 5  
 ROS detoxification, 5, 6
- Glutathione transferase (GSTs), 191–192
- GPx. *See* Glutathione peroxidase (GPx)
- GRXs. *See* Glutaredoxins (GRXs)
- GSH. *See* Glutathione (GSH)
- GSTs. *See* Glutathione transferase (GSTs)
- H**
- HeLa cells, 37, 108, 122, 123
- Homeostasis  
 ASM, 104  
 bioenergetic, 31  
 calcium, asthma, 63  
 and cell death, 178  
 cell signaling, 17  
 lung tissue, 146
- Hyperoxia  
 CL and PS, 128  
 environmental oxidants, 127  
 lung injury, 127  
 neonatal rats, 198–199
- Hypertension  
 and cancer, 2  
 and CPAP, 75  
 and OSA, 73  
 pulmonary arterial, 13
- Hypoxia  
 alveolar epithelial responses,  
 163–164  
 environmental oxidants, 127  
 pulmonary vasoconstriction, 164–165
- Hypoxia-inducible factor (HIF), 84, 163–164,  
 166–167
- Hypoxic vasoconstriction, 164–165, 171
- I**
- Idiopathic pulmonary fibrosis (IPF),  
 14, 169
- IH. *See* Intermittent hypoxia (IH)
- Interleukin-4 (IL-4), 54–55
- Intermittent hypoxia (IH)  
 autonomic and cardiovascular function,  
 rodents, 75–78
- hypoxia, 73  
 oxidative stress, 80–84  
 ROS generation, 84
- IPF. *See* Idiopathic pulmonary fibrosis (IPF)
- K**
- Kelch-like ECH-associated protein 1  
 (KEAP1), 35, 37, 41
- L**
- “Latch-bridge” hypothesis, 102
- Linoleate hydroperoxide (LOOH),  
 129–130
- Lipid peroxidation  
 CL, 122–124  
 eicosanoids and lung mitochondria,  
 129–132  
 free radical scavengers and antioxidants,  
 133  
 PUFAs, 121–122  
 reactive carbonyls, 122  
 thiol-redox-stabilizing enzymes, 122  
 tobacco smoke, 128–129
- LOOH. *See* Linoleate hydroperoxide  
 (LOOH)
- Lung aging, 182–184
- Lung cancer  
 A549 cells, 131  
 bronchial epithelial cells, 148  
 carcinogens, 126  
 lipid peroxidation, 126
- Lung development  
 adult lung, 182  
 aging, 183–184  
 branching morphogenesis, 183  
 cellular injury, toxicant exposure,  
 194–195  
 children, 183  
 flavin-containing monooxygenases, 194  
 potential toxicity, 182–183  
 sulfotransferases, 194
- Lung diseases  
 acute and chronic, 34  
 apoptosis (*see* Apoptosis)  
 asthma, 12  
 ATM and ATR, 147  
 cellular response to DNA damage, 153  
 DNA damage, 152–153  
 energy metabolism, 33  
 ETC, 34  
 hyperoxia, 152

- lipid peroxidation, 129
  - mitochondrial dysfunction, 151–152
  - mitochondrial fractions, 152
  - oxidant stress, 35
  - oxygen supplementation therapy, 151–152
  - prohibitin expression, 35
  - pro-oxidant/toxicant exposure, 31
  - pulmonary
    - epithelial cells, 143
    - fibrosis, 12
  - ROS-mediated DNA damage, 152
- M**
- Metabolism**
- arachidonic acid, 132
  - in cancer cells, 165
  - glucose, 130
  - mitochondrial, 7, 35
  - neurons and muscle cells, 53
  - and protection, 38
- Mitochondria**
- aerobic cell powerhouse, 2
  - age-related factors, 179, 180
  - asthma, 55
  - ATP, 31
  - autophagy, 32
  - buffering organelles, 63
  - cancer
    - anaerobic and aerobic glycolysis, 165
    - DNA mutations, 165–166
    - glucose metabolism, 165
    - MPT, 167
  - Clara cells, 180
  - description, 118–119
  - dysfunction, 181–182
  - environmental factors, 55
  - free radical scavengers, 133
  - healthy and injured cell, 178, 179
  - lipid peroxidation, 121–124
  - membrane lipid organization, 120–121
  - NADPH reduction, 7
  - oxidative phosphorylation, 104
  - oxidative stress and ROS, 119–120
  - paternal sperm, 53
  - RNS and ROS, 5
  - sepsis and multiple organ dysfunction syndrome, 11
  - toxic compounds, 178
- Mitochondrial DNA (mtDNA)**
- chronic oxidative damage, 144
  - encoded, nuclear genome, 144
  - ETC proteins, 181
  - mouse lung, 181
  - mutations
    - anaerobic and aerobic glycolysis, 166
    - impairment, respiratory chain functions, 165
    - oncogenesis, 166
    - ROS, 165–166
    - SDH, 166–167
    - tumor cell proliferation, 166
  - 8oxoG staining, 144
- Mitochondrial dysfunction**
- bronchial epithelia, asthmatic mice, 56–57
  - description, 181–182
  - lung diseases, 33–35, 151–152
  - and NRF2 impairment, 39–41
  - ROS, 57
- Mitochondrial excitation-energy coupling**
- ASM, 93–94
  - asthma, 93
  - Ca<sup>2+</sup> signaling (*see* Ca<sup>2+</sup> signaling)
  - intracellular Ca<sup>2+</sup>, 94
- Mitochondrial genetics**
- A12308G mutation, 55
  - environmental factors, 55
  - human mitochondrial genome, 53–54
  - IL-4, 54–55
  - Th2 cytokines, 54
- Mitochondrial outer membrane**
- permeabilization (MOMP), 31, 32, 118
- Mitochondrial permeability transition (MPT), 167**
- Mitochondrial phosphoglycerate mutase family member 5 (PGAM5), 36–37**
- Mitochondria-targeted antioxidant therapy**
- cell permeable small peptide
    - antioxidants, 10
  - Mito-CP, 9–10
  - Mito-Q, 9
  - natural antioxidants, 8
  - SkQ1, 10
  - TPP, 9
- Mitochondria-targeted carboxy proxyl (Mito-CP), 9–10**
- Mitophagy, 32, 42**
- MOMP. *See* Mitochondrial outer membrane permeabilization (MOMP)**
- MPT. *See* Mitochondrial permeability transition (MPT)**
- mtDNA. *See* Mitochondrial DNA (mtDNA)**
- Muscle sympathetic nerve activity (MSNA), 74**

**N**

- NADPH oxidase (NOX)  
 and GSH, 7  
 and intracellular calcium chelator, 15  
 and isocitrate dehydrogenase (IDH), 6  
 mitochondrial, 7  
 reduction, 7  
 ROS and RNS, 3
- NRF2. *See* Nuclear factor erythroid 2-related factor 2 (NRF2)
- NRF2-antioxidant response element (NRF2-ARE) pathway  
 KEAP1, 35  
 mitochondrial  
   biogenesis, 36, 37  
   stress, 37, 38  
 nuclear DNA, 36  
 PGAM5, 36
- Nuclear DNA  
 cellular response, 144–145  
 dynamic chromatin structure, 143–144  
 histone proteins, 143
- Nuclear factor erythroid 2-related factor 2 (NRF2)  
 apoptosis and autophagy, 31–33  
 GSH signaling, 38–39  
 lung diseases, 33–35  
 mitochondrial biogenesis and oxidative stress  
   antioxidant enzymes/molecules, 31  
   cytochrome *c*, 29  
   nuclear genome, 29–30  
   physiological/pathological stimuli, 30  
   redox balance, 30  
   ROS and RNS, 30  
 mitochondrial dysfunction, 39–41  
 NRF2-ARE pathway, 35–38  
 oxidant stress, 8  
 redox-sensitive transcription factor, 7

**O**

- Obstructive sleep apnea (OSA)  
 autonomic and cardiovascular functions, 73–75  
 CPAP, 75  
 description, 72  
 intermittent hypoxia (IH), 72–73  
 oxidative stress (*see* Oxidative stress)  
 rodents exposed, IH, 75–78  
 ROS generation during IH, 84
- Oxidant-induced peroxidation, 40, 122, 133
- Oxidative damage  
 A549 cells, 125

- antiapoptotic pathways, 143
- antioxidants, 17, 30
- B[a]P, 126
- cardiolipin, 58
- granulocytes, 12
- macromolecules, 143
- Oxidative stress  
 animal models, IH, 80–84  
 cytosolic mammalian, 6  
 ETC, 82  
 glutathionylation, 39  
 hypoxia-reperfusion injury, 78  
 IH-induced  
   responses, 81, 84  
   ROS generation, 80–81  
 markers, 79  
 mitochondrial biogenesis, 29–31  
 mitochondrial complex I inhibition, 83  
 mitochondria-targeted antioxidants, 11  
 Mito-Q, 6  
 Nox, 82  
 NRF2-ARE pathway, 36  
 OSA-induced autonomic and blood pressure, 78–80  
 prooxidant enzymes, 58  
 ROS, 81–82, 119–120
- Ozone, 182, 199–200

**P**

- p53  
 DNA repair, 148  
 embryonic stem cells, 149–150  
 genes promoting stem cell, 150  
 and mitochondria, 152  
 transcription factor, 147  
 ubiquitin-dependent ligases, 147
- PAH. *See* Pulmonary arterial hypertension (PAH)
- Peripheral benzodiazepine receptor (PBR), 62–63
- Permeability transition pore (PTP), 167, 168, 178
- Peroxiredoxins (Prxs), 7, 31, 120, 122, 189
- Polyunsaturated fatty acids (PUFAs)  
 acrolein, 122  
 CL, 122, 127  
 description, 121  
 hydroperoxides, 129, 131  
 membrane PLs, 122
- Post-translational modification, 30, 78, 79, 83, 147
- Pro-oxidant enzymes, 31, 40
- Prxs. *See* Peroxiredoxins (Prxs)

PTP. *See* Permeability transition pore (PTP)  
 PUFAs. *See* Polyunsaturated fatty acids (PUFAs)  
 Pulmonary arterial hypertension (PAH), 13, 125, 126, 196  
 Pulmonary disorders  
   acute lung injury, 11–12  
   allergic bronchial asthma, 12–13  
   BPD, 14–16  
   fibrosis, 13–14  
   mitochondrion, 11  
   PAH, 13  
 Pulmonary fibrosis, 13–14, 125, 143, 150  
 Pulmonary toxicity, 197, 200, 201

**R**

Reactive nitrogen species (RNS)  
   ADMA, 59  
   cell signaling, 30  
   mitochondrial and extramitochondrial sources, 121  
   mtNOS, 119  
   nitric oxide, 59–60  
   NOS, 4, 59  
   peroxynitrite formation, 59  
   proapoptotic pathways, 119  
   reactive species, 3  
 Reactive oxygen species (ROS)  
   antiapoptotic pathways, 143  
   antioxidant enzymes/molecules, 31  
   catalase, 5  
   cellular functions, 142  
   enzymatic antioxidants, 143  
   excessive production, 171  
   exogenous sources, 30  
   GPx, 5–6  
   hyperoxia, 152  
   hypoxia, 34, 151, 164  
   lipid peroxidation, 123  
   15-lipoxygenase, 58  
   mammalian cells, 5  
   mammalian mitochondrial matrix, 3  
   mechanism, 132  
   mitochondrial damage, 151–152  
   mitochondrial oxidative phosphorylation, 3, 4  
   mitochondria-targeted antioxidant therapy, 8–10  
   nonenzymatic antioxidants, 142  
   Nrf2, 7–8  
   oxidative stress, 119–120  
   PMN cells, 143  
   Prxs, 7

  pulmonary disorders, 11–16  
   reactive molecules, 3  
   respiratory chain, 165  
   reversible S-glutathionylation, 39  
   SDH, 167  
   sirtuins, 8  
   SOD, 5  
   superoxide anion, 142  
   Trxs, 6–7  
 Remodeling  
   actin-myosin, 100–101  
   airway, bronchial epithelial injury, 61–63  
   apoptosis and lung, 167–170  
 Respiratory and lung diseases  
   atmospheric residual oil fly ash (ROFA) PM, 124  
   bipyridium herbicide, 125  
   cadmium (Cd), 124  
   endosymbiotic theory, 2  
   lung injury, 2  
   mitochondria, 2  
   paraquat, 125  
   particulate matter (PM), 124  
   PM air pollution, 124–125  
   RNS (*see* Reactive nitrogen species (RNS))  
   ROS (*see* Reactive oxygen species (ROS))  
 Respiratory epithelium, 142, 145, 153  
 RNS. *See* Reactive nitrogen species (RNS)  
 Rodents, IH  
   advantages, 75  
   blood pressure elevation, 76  
   catecholamine secretion-synthesis coupling, 77–78  
   chemo-and baroreflex functions, 77  
   SNA, 77  
   vasoactive hormones, 77  
 ROS. *See* Reactive oxygen species (ROS)

**S**

SDH. *See* Succinate dehydrogenase (SDH)  
 S-glutathionylation  
   mitochondrial enzymes, 39  
   ryanodine receptor-2, 83  
 Sirtuins, 8  
 Skeletal muscle dysfunction (SMD), 170–171  
 SNA. *See* Sympathetic nerve activity (SNA)  
 SOD. *See* Superoxide dismutase (SOD)  
 Succinate dehydrogenase (SDH), 166–167, 170

Superoxide dismutase (SOD)  
antioxidant defense mechanism, 5  
asthmatic airway, 58  
description, 185  
expression, antioxidant enzyme protein,  
185–186  
lung cytosol, 128  
mammalian cells, 5  
Sympathetic nerve activity (SNA)  
and chemo-and baroreflex function, 77  
IH effects, 77

**T**

Thioredoxin reductase 2 (TXNRD2), 39  
Thioredoxins (Trxs), 6–7, 16, 39,  
122, 142  
TNF. *See* Tumor necrosis factor (TNF)  
Tobacco smoke  
acrolein, 122, 130  
cigarette smoke extract (CSE), 129  
DNA damage, 149  
environmental factors, 129  
ETS, 195–196

and lipid peroxidation, 128–129  
lung damage and pulmonary diseases,  
128–129  
plethora toxic compounds, 128  
respiratory diseases, 129  
Triphenylphosphonium (TPP), 9, 133  
Trxs. *See* Thioredoxins (Trxs)  
Tumor necrosis factor (TNF), 11, 31, 64,  
124, 167  
TXNRD2. *See* Thioredoxin reductase 2  
(TXNRD2)

**V**

Vasoconstrictors, 74–75, 77  
Viral infections, 63–64

**W**

Warburg effect, 165, 166

**X**

Xenobiotic-metabolizing enzyme systems, 189